[1]朱贝利,刘 辉,耿硕章,等.心肌梗死后缺血性心肌病心衰患者血浆半乳糖凝集素3的表达及其临床意义[J].医学信息,2020,33(15):61-64.[doi:10.3969/j.issn.1006-1959.2020.15.020]
　ZHU Bei-li,LIU Hui,GENG Shuo-zhang,et al.Expression of Plasma Galectin-3 in Patients with Ischemic Cardiomyopathy and Heart Failure After Myocardial Infarction and Its Clinical Significance[J].Medical Information,2020,33(15):61-64.[doi:10.3969/j.issn.1006-1959.2020.15.020]
点击复制

心肌梗死后缺血性心肌病心衰患者血浆半乳糖凝集素3的表达及其临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年15期
页码:
61-64
栏目:
论著
出版日期:
2020-08-01

文章信息/Info

Title:
Expression of Plasma Galectin-3 in Patients with Ischemic Cardiomyopathy and Heart Failure After Myocardial Infarction and Its Clinical Significance
文章编号:
1006-1959（2020）15-0061-04
作者:
朱贝利; 刘 辉; 耿硕章; 郭军霞; 张永春
新乡医学院第一附属医院心内科，河南 新乡 453100
Author(s):
ZHU Bei-li; LIU Hui; GENG Shuo-zhang; GUO Jun-xia; ZHANG Yong-chun
Department of Cardiology,the First Affiliated Hospital of Xinxiang Medical College,Xinxiang 453100,Henan,Chin
关键词:
心肌梗死; 缺血性心肌病; 心力衰竭; 半乳糖凝集素3
Keywords:
Myocardial infarction; Ischemic cardiomyopathy; Heart failure; Galectin 3
分类号:
R541.6+1；R542.22
DOI:
10.3969/j.issn.1006-1959.2020.15.020
文献标志码:
A
摘要:
目的 研究心肌梗死后缺血性心肌病（ICM）心力衰竭（心衰）患者血浆中半乳糖凝集素3（Gal-3）的表达水平变化，并探讨其临床意义。方法 选取2018年7月~2019年2月在我院收治的29例心肌梗死后ICM心衰患者设为心梗后ICM心衰组，27例非心肌梗死后ICM心衰患者设为非心梗后ICM心衰组，21例非ICM心衰患者设为非ICM心衰组，22例正常对照患者设为正常对照组。采用酶联免疫吸附测定法检测四组患者血浆中Gal-3及氨基末端脑钠肽前体（Nt-proBNP）的表达水平，并用超声心动图检查其左房内径（LAD）、左心室舒张末期内径（LVEDD）、左心室射血分数（LVEF）。比较四组一般资料、血浆Gal-3水平，分析Gal-3水平对心力衰竭及心梗后ICM心衰诊断的敏感度与特异性、四组Gal-3水平与心功能的相关性。结果 四组患者Gal-3水平比较，差异有统计学意义（P＜0.05），其中心梗后ICM心衰组Gal-3水平最高。心梗后ICM心衰组Gal-3水平均高于非心梗后ICM心衰组、非ICM心衰组、正常对照组（P＜0.05）；非心梗后ICM心衰组、非ICM心衰组Gal-3水平均高于正常对照组（P＜0.05）；非心梗后ICM心衰组和非ICM心衰组Gal-3水平比较，差异无统计学意义（P＞0.05）；Gal-3对心力衰竭诊断的ROC AUC为0.989，具有较好的诊断效能。Gal-3对心梗后ICM心衰诊断的ROC AOC为0.753，具有一定的诊断效能。四组LVEDD、LVEF比较，差异有统计学意义（P＜0.05），心梗后ICM心衰组LVEDD最高，LVEF最低。Spearman相关性分析显示，心梗后ICM心衰组Gal-3水平与LVEDD成正相关（r=0.407，P＜0.05），LVEF成负相关（r=-0.620，P＜0.05），与LAD无相关性（P＞0.05）；非心梗后ICM心衰组、非ICM心衰组、正常对照组Gal-3水平与其LAD、LVEDD、LVEF均无相关性（P＞0.05）。结论 心肌梗死后缺血性心肌病心衰患者血浆中Gal-3表达水平升高，并且与患者左室结构和功能变化存在相关性，在临床上对此类患者病情及预后评估具有重要作用。
Abstract:
Objective To study the changes of galectin-3 (Gal-3) expression in plasma of patients with ischemic cardiomyopathy (ICM) and heart failure (heart failure) after myocardial infarction, and to explore its clinical significance.Methods 29 patients with ICM heart failure after myocardial infarction who were admitted to our hospital from July 2018 to February 2019 were selected as the post-MI heart failure group, and 27 patients with non-myocardial infarction ICM heart failure were set as non-MI In the post-ICM heart failure group, 21 non-ICM heart failure patients were set as the non-ICM heart failure group, and 22 normal control patients were set as the normal control group. Enzyme-linked immunosorbent assay was used to detect the expression levels of Gal-3 and Nt-proBNP in the plasma of the four groups of patients, and the left atrial inner diameter (LAD) and left ventricular end-diastole were checked by echocardiography inner diameter (LVEDD), left ventricular ejection fraction (LVEF). Compare the four groups of general data, plasma Gal-3 levels, analyze the sensitivity and specificity of Gal-3 levels in the diagnosis of heart failure and ICM heart failure after myocardial infarction, and analyze the correlation between Gal-3 levels and cardiac function in the four groups.Results The Gal-3 levels of the four groups were compared,the difference was statistically significant (P＜0.05). The Gal-3 level was the highest in the ICM heart failure group after central infarction. The level of Gal-3 in the ICM heart failure group after myocardial infarction was higher than that of the non-ICM heart failure group, non-ICM heart failure group, and normal control grou(P＜0.05); The levels of Gal-3 in the ICM heart failure group and the non-ICM heart failure group after non-MI heart failure were higher than those in the normal control group(P＜0.05); the non-ICM heart failure group and the non-ICM heart failure group after myocardial infarction,there was no statistically significant difference in the level of Gal-3 (P＞0.05);The ROC AUC of Gal-3 for the diagnosis of heart failure was 0.989, which has good diagnostic efficiency. The ROC AOC of Gal-3 for the diagnosis of ICM heart failure after myocardial infarction is 0.753, which has certain diagnostic efficiency.The differences of LVEDD and LVEF of four groups were statistically significant (P＜0.05). The ICM heart failure group after myocardial infarction had the highest LVEDD and the lowest LVEF. Spearman correlation analysis showed that the level of Gal-3 in the ICM heart failure group after myocardial infarction was positively correlated with LVEDD (r=0.407,P＜0.05), and LVEF was negatively correlated (r=-0.620,P＜0.05),there was no significant correlation with LAD correlation (P＞0.05); there was no correlation between the level of Gal-3 in non-MI heart failure group, non-ICM heart failure group, and normal control group with LAD, LVEDD and LVEF after non-MI (P＞0.05).Conclusion After myocardial infarction, the expression level of Gal-3 in the plasma of patients with ischemic cardiomyopathy and heart failure is increased, and it is correlated with the changes of left ventricular structure and function. It plays an important role in clinical evaluation of the condition and prognosis of such patients.

参考文献/References:

[1]裴志勇,赵玉生,李佳月,等.慢性心力衰竭住院患者病因学及近期预后的15年变迁[J].中华心血管病杂志,2011,39(5):434-439.[2]Velavan P,Khan NK,Goode K,et al.Predictors of short term mortality in heart failure—Insights from the Euro Heart Failuresurvey[J].International Journal of Cardiology,2010,138(1):63-69.[3]孙润民,王琼英,齐苗苗,等.急性心肌梗死后心力衰竭预测因素的研究进展[J].中华心血管病杂志,2019,47(11):923-926.[4]Dumic J,Dabelic S.Galectin-3:an open-ended story[J].Biochimica et Biophysica Acta,2006,1760(4):616-635.[5]Yu L,Ruifrok WPT,Meissner M,et al.Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis[J].Circulation:Heart Failure,2013,6(1):107-117.[6]Mackinnon A,Farnworth SP,Henderson N,et al.Regulation of alternative macrophage activation by galectin-3[J].Journal of Immunology,2008,180(4):2650-2658.[7]李国庆,郭自同.缺血性心肌病性冠心病概述[J].医学与哲学,2012,33(16):20-24.[8]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志(中英文),2018,2(4):196-225.[9]王华,李莹莹,柴坷,等.中国住院心力衰竭患者流行病学及治疗现状[J].中华心血管病杂志,2019,47(11):865-874.[10]国家卫生计生委合理用药专家委员会,中国药师协会.冠心病合理用药指南(第2版)[J].中国医学前沿杂志(电子版),2018,10(6):7-136.[11]李艳萍,王晨霞.血清半乳糖凝集素-3与急性冠状动脉综合征关系研究进展[J].心肺血管病杂志,2018,37(10):944-946.[12]刘丹,张静,刘英丽,等.多项标志物联合检测在心力衰竭中的应用[J].标记免疫分析与临床,2015,22(10):982-985.[13]雷亮,胡建新.半乳糖凝集素-3与心力衰竭关系的研究进展[J].广东医学,2015 (11):1770-1772.[14]Medvedeva EA,Berezin II,Surkova EA,et al.Galectin-3 in patients with chronic heart failure:association with oxidative stress, inflammation,renal dysfunction and prognosis[J].Minerva Cardioangiologica,2016,64(6):595-602.[15]Lok DJA,Meer PVD,Lipsic E,et al.Prognostic value of galectin-3,a novel marker of fibrosis,in patients with chronic heart failure:data from the DEAL-HF study[J].Clinical Research in Cardiology Official Journal of the German Cardiac Society,2010,99(5):323-328.[16]郑颖,李强.半乳糖凝集素3在心肌梗死后慢性心力衰竭患者血清中的表达及其与患者心功能的相关性分析[J].中国循环杂志,2018,33(4):332-335.[17]Chen K,Jiang RJ,Wang CQ,et al.Predictive value of plasma galectin-3 in patients with chronic heart failure[J].European Review for Medical and Pharmacological Sciences,2013,17(8):1005-1011.[18]Lok D J,Lok S I,Pieta W,et al.Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure[J].Clinical Research in Cardiology,2013,102(2):103-110.[19]金朦超,魏思琪,高蓉蓉,等.半乳糖凝集素3与心力衰竭心室重构关系的研究进展[J].临床心血管病杂志,2016,32(5):441-445.收

相似文献/References:

[1]冯 湧.新一代抗凝血药阿加曲班的临床应用进展[J].医学信息,2018,31(02):43.[doi:10.3969/j.issn.1006-1959.2018.02.015]
　FENG Yong.Progress in Clinical Application of the New Generation Anticoagulant Agatripine[J].Medical Information,2018,31(15):43.[doi:10.3969/j.issn.1006-1959.2018.02.015]
[2]翟公伟,赵培华,滑 艳.30岁以下急性ST段抬高型心肌梗死患者临床特点分析[J].医学信息,2018,31(05):81.[doi:10.3969/j.issn.1006-1959.2018.05.026]
　ZHAI Gong-wei,ZHAO Pei-hua,HUA Yan.Clinical Characteristics of Acute ST-segment Elevation Myocardial Infarction under 30 Years of Age[J].Medical Information,2018,31(15):81.[doi:10.3969/j.issn.1006-1959.2018.05.026]
[3]杜浩珲.溶栓后PCI与pPCI治疗急性ST段抬高型心肌梗死的 临床效果研究[J].医学信息,2018,31(08):69.[doi:10.3969/j.issn.1006-1959.2018.08.021]
　DU Hao-hun.Clinical Effect of PCI and pPCI on Acute ST Segment Elevation Myocardial Infarction after Thrombolysis[J].Medical Information,2018,31(15):69.[doi:10.3969/j.issn.1006-1959.2018.08.021]
[4]宋俊燕,张 毅.重组人尿激酶原在急性ST段抬高型心肌梗死中的 疗效及并发症分析[J].医学信息,2018,31(11):133.[doi:10.3969/j.issn.1006-1959.2018.11.042]
　SONG Jun-yan,ZHANG Yi.Therapeutic Efficacy and Complications of Recombinant Human Pro-urokinase in Acute ST-elevation Myocardial Infarction[J].Medical Information,2018,31(15):133.[doi:10.3969/j.issn.1006-1959.2018.11.042]
[5]李 晶,黄 波.抗血小板药物治疗心血管疾病的研究现状[J].医学信息,2022,35(10):83.[doi:10.3969/j.issn.1006-1959.2022.10.020]
　LI Jing,HUANG Bo.Research Status of Antiplatelet Drugs in the Treatment of Cardiovascular Diseases[J].Medical Information,2022,35(15):83.[doi:10.3969/j.issn.1006-1959.2022.10.020]
[6]汤海霞,班 涛.大黄素与心血管疾病的研究[J].医学信息,2022,35(11):19.[doi:10.3969/j.issn.1006-1959.2022.11.006]
　TANG Hai-xia,BAN Tao.Research on Emodin and Cardiovascular Diseases[J].Medical Information,2022,35(15):19.[doi:10.3969/j.issn.1006-1959.2022.11.006]
[7]李素军.早期心脏康复运动治疗方案对急性非ST段抬高 心肌梗死的效果观察[J].医学信息,2018,31(15):89.[doi:10.3969/j.issn.1006-1959.2018.15.027]
　LI Su-jun.Effect of Early Cardiac Rehabilitation Exercise on Acute Non-ST-Elevation Myocardial Infarction[J].Medical Information,2018,31(15):89.[doi:10.3969/j.issn.1006-1959.2018.15.027]
[8]王 铮.不同院前急救方式对心肌梗死后急性左心衰竭救治效果及预后的影响[J].医学信息,2022,35(12):169.[doi:10.3969/j.issn.1006-1959.2022.12.042]
　WANG Zheng.Effect of Different Pre-hospital Emergency Methods on Treatment and Prognosis of Acute Left Heart Failure After Myocardial Infarction[J].Medical Information,2022,35(15):169.[doi:10.3969/j.issn.1006-1959.2022.12.042]
[9]邓 伟.冠脉无复流的危险因素及治疗[J].医学信息,2021,34(03):43.[doi:10.3969/j.issn.1006-1959.2021.03.013]
　DENG Wei.Risk Factors and Treatment of No-reflow of Coronary Artery[J].Medical Information,2021,34(15):43.[doi:10.3969/j.issn.1006-1959.2021.03.013]
[10]金 鹏,周炳凤.去甲肾上腺素在心肌梗死合并低血压中的应用[J].医学信息,2020,33(07):57.[doi:10.3969/j.issn.1006-1959.2020.07.017]
　JIN Peng,ZHOU Bing-feng.Application of Norepinephrine in Myocardial Infarction with Hypotension[J].Medical Information,2020,33(15):57.[doi:10.3969/j.issn.1006-1959.2020.07.017]

更新日期/Last Update: 1900-01-01